We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein.
- Authors
Raadsen, Matthijs P; Dahlke, Christine; Fathi, Anahita; Lamers, Mart M; van den Doel, Petra; Zaeck, Luca M; Royen, Martin E van; Bruin, Erwin de; Sikkema, Reina; Koopmans, Marion; Gorp, Eric C M van; Sutter, Gerd; Vries, Rory D de; Addo, Marylyn M; Haagmans, Bart L
- Abstract
Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)–associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.
- Subjects
MIDDLE East; ANKARA (Turkey); VACCINIA; MONKEYPOX; VIRAL antibodies; MIDDLE East respiratory syndrome; VACCINATION; CORONAVIRUS diseases
- Publication
Journal of Infectious Diseases, 2023, Vol 228, Issue 5, p586
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/jiad052